Risk of major cardiovascular and neurologic events with obstructive sleep apnea among patients with atrial fibrillation

Atrial Fibrillation

Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial

J Am Heart Assoc.

Pol T, Held C, Westerbergh J, Lindbäck J, Alexander JH, Alings M, Erol C, Goto S, Halvorsen S, Huber K, Hanna M, Lopes RD, Ruzyllo W, Granger CB, Hijazi Z

doi: 10.1161/JAHA.117.007444.

Cardiovascular Risk and Diseases

Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial

JAMA Cardiol.

Verma S, Bain SC, Buse JB, Idorn T, Rasmussen S, Ørsted DD, Nauck MA

doi: 10.1001/jamacardio.2019.3080.

Atrial Fibrillation

Associations of Obstructive Sleep Apnea With Atrial Fibrillation and Continuous Positive Airway Pressure Treatment

JAMA Cardiol.

Linz D, McEvoy RD, Cowie MR, Somers VK, Nattel S, Lévy P, Kalman JM, Sanders P

doi: 10.1001/jamacardio.

Cardiovascular Risk and Diseases

Prognostic Value of the CHADS2 Score for Adverse Cardiovascular Events in Coronary Artery Disease Patients Without Atrial Fibrillation-A Multi-Center Observational Cohort Study

J Am Heart Assoc.

Tabata N, Yamamoto E, Hokimoto S, Yamashita T, Sueta D, Takashio S, Arima Y, Izumiya Y, Kojima S, Kaikita K, Matsui K, Fujimoto K, Sakamoto K, Shimomura H, Tsunoda R, Hirose T, Nakamura N, Sakaino N, Nakamura S, Yamamoto N, Matsumura T, Kajiwara I, Koide S, Sakamoto T, Nakao K, Oshima S, Tsujita K; Kumamoto Intervention Conference Study (KICS) Investigators

doi: 10.1161/JAHA.117.006355.

Atrial FibrillationThrombosis and StrokeTherapy and Intervention

Long-term Thromboembolic Risk in Patients With Postoperative Atrial Fibrillation After Coronary Artery Bypass Graft Surgery and Patients With Nonvalvular Atrial Fibrillation

JAMA Cardiol.

Butt JH, Xian Y, Peterson ED, Olsen PS, Rørth R, Gundlund A, Olesen JB, Gislason GH, Torp-Pedersen C, Køber L, Fosbøl EL

doi: 10.1001/jamacardio.

Atrial Fibrillation

Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation

J Am Coll Cardiol.

Osmancik P, Herman D, Neuzil P, Hala P, Taborsky M, Kala P, Poloczek M, Stasek J, Haman L, Branny M, Chovancik J, Cervinka P, Holy J, Kovarnik T, Zemanek D, Havranek S, Vancura V, Opatrny J, Peichl P, Tousek P, Lekesova V, Jarkovsky J, Novackova M, Benesova K, Widimsky P, Reddy VY, PRAGUE-17 Trial Investigators.

doi: 10.1016/j.jacc.2020.04.067.

Heart, Artery and Coronary DiseasesMyocardial InfarctionTherapy and Intervention

Incomplete Revascularization Is Associated With an Increased Risk for Major Adverse Cardiovascular Events Among Patients Undergoing Noncardiac Surgery

JACC Cardiovasc Interv.

Armstrong EJ, Graham LA, Waldo SW, Valle JA, Maddox TM, Hawn MT Author information

doi: 10.1016/j.jcin.2016.11.001.

RECOMMENDED

Cardiovascular Risk and DiseasesMyocardial InfarctionThrombosis and Stroke

Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial

Lancet.

Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB, Howard G, Pearson TA, Rothwell PM, Ruilope LM, Tendera M, Tognoni G, ARRIVE Executive Committee

doi: 10.1016/S0140-

Atrial Fibrillation

Association of Anticoagulant Therapy With Risk of Fracture Among Patients With Atrial Fibrillation

JAMA Intern Med.

Lutsey PL, Norby FL, Ensrud KE, MacLehose RF, Diem SJ, Chen LY, Alonso A

doi: 10.1001/jamainternmed.2019.5679.

Related content

Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial

Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial

Associations of Obstructive Sleep Apnea With Atrial Fibrillation and Continuous Positive Airway Pressure Treatment

Prognostic Value of the CHADS2 Score for Adverse Cardiovascular Events in Coronary Artery Disease Patients Without Atrial Fibrillation-A Multi-Center Observational Cohort Study

Long-term Thromboembolic Risk in Patients With Postoperative Atrial Fibrillation After Coronary Artery Bypass Graft Surgery and Patients With Nonvalvular Atrial Fibrillation

Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation

Incomplete Revascularization Is Associated With an Increased Risk for Major Adverse Cardiovascular Events Among Patients Undergoing Noncardiac Surgery

Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial

Association of Anticoagulant Therapy With Risk of Fracture Among Patients With Atrial Fibrillation